KR100854872B1 - 바소프레신 길항제로서의 트리아졸 유도체 - Google Patents
바소프레신 길항제로서의 트리아졸 유도체 Download PDFInfo
- Publication number
- KR100854872B1 KR100854872B1 KR1020067012328A KR20067012328A KR100854872B1 KR 100854872 B1 KR100854872 B1 KR 100854872B1 KR 1020067012328 A KR1020067012328 A KR 1020067012328A KR 20067012328 A KR20067012328 A KR 20067012328A KR 100854872 B1 KR100854872 B1 KR 100854872B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- triazol
- mmol
- compound
- chloro
- Prior art date
Links
- 0 C*(CC1)CCC1C1=*C*=C(C*2*=CC=*2)*1c(cc1)ccc1N Chemical compound C*(CC1)CCC1C1=*C*=C(C*2*=CC=*2)*1c(cc1)ccc1N 0.000 description 7
- JPFHACPFESGOSX-UHFFFAOYSA-N CC(C)(C)OC(CC(CC1)CCC1c1nnc(CCl)[o]1)=O Chemical compound CC(C)(C)OC(CC(CC1)CCC1c1nnc(CCl)[o]1)=O JPFHACPFESGOSX-UHFFFAOYSA-N 0.000 description 1
- TWSJAOFEDPFMOG-UHFFFAOYSA-N CC(C)(C)OC(N1CC(C(NN)=O)OCC1)=O Chemical compound CC(C)(C)OC(N1CC(C(NN)=O)OCC1)=O TWSJAOFEDPFMOG-UHFFFAOYSA-N 0.000 description 1
- HCUVVJINIWWCCR-UHFFFAOYSA-N CC(Nc(cc1)ccc1Cl)=S Chemical compound CC(Nc(cc1)ccc1Cl)=S HCUVVJINIWWCCR-UHFFFAOYSA-N 0.000 description 1
- DAWFJGMMMBJQBB-UHFFFAOYSA-N CCOC(C[n]1nncc1)=O Chemical compound CCOC(C[n]1nncc1)=O DAWFJGMMMBJQBB-UHFFFAOYSA-N 0.000 description 1
- RHLCVNFOJJSRPF-UHFFFAOYSA-N CCOC1(C[n]2nccn2)CC1 Chemical compound CCOC1(C[n]2nccn2)CC1 RHLCVNFOJJSRPF-UHFFFAOYSA-N 0.000 description 1
- LMOMKEFLZHKPDE-UHFFFAOYSA-N CCc1nnc(C(CC2)CCN2C(c(cc2)ccc2Cl)=O)[o]1 Chemical compound CCc1nnc(C(CC2)CCN2C(c(cc2)ccc2Cl)=O)[o]1 LMOMKEFLZHKPDE-UHFFFAOYSA-N 0.000 description 1
- FVXZLSQAROCYIW-UHFFFAOYSA-N Cc1nnc(C2CCNCC2)[n]1-c(cc1)ccc1Cl Chemical compound Cc1nnc(C2CCNCC2)[n]1-c(cc1)ccc1Cl FVXZLSQAROCYIW-UHFFFAOYSA-N 0.000 description 1
- NSZFJVHSPRYQOF-UHFFFAOYSA-N FC(OCc1nnc(C2CCNCC2)[n]1-c(cc1)ccc1Cl)(F)F Chemical compound FC(OCc1nnc(C2CCNCC2)[n]1-c(cc1)ccc1Cl)(F)F NSZFJVHSPRYQOF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0329693A GB0329693D0 (en) | 2003-12-22 | 2003-12-22 | Compounds useful in therapy |
GB0329693.6 | 2003-12-22 | ||
GB0408789A GB0408789D0 (en) | 2004-04-20 | 2004-04-20 | Triazole derivatives |
GB0408789.6 | 2004-04-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060101546A KR20060101546A (ko) | 2006-09-25 |
KR100854872B1 true KR100854872B1 (ko) | 2008-08-28 |
Family
ID=34740750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067012328A KR100854872B1 (ko) | 2003-12-22 | 2004-12-09 | 바소프레신 길항제로서의 트리아졸 유도체 |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1701959A1 (es) |
JP (1) | JP4698604B2 (es) |
KR (1) | KR100854872B1 (es) |
AP (1) | AP2331A (es) |
AR (1) | AR047340A1 (es) |
AU (1) | AU2004309164B2 (es) |
BR (1) | BRPI0417267A (es) |
CA (1) | CA2551038C (es) |
CR (1) | CR8481A (es) |
DO (1) | DOP2004001062A (es) |
EA (1) | EA010132B1 (es) |
EC (1) | ECSP066647A (es) |
GE (1) | GEP20084571B (es) |
HK (1) | HK1095822A1 (es) |
IL (1) | IL176349A (es) |
IS (1) | IS8472A (es) |
MA (1) | MA28393B1 (es) |
NL (1) | NL1027833C2 (es) |
NO (1) | NO20063380L (es) |
OA (1) | OA13347A (es) |
PA (1) | PA8620501A1 (es) |
PE (1) | PE20051051A1 (es) |
TW (1) | TWI287541B (es) |
UY (1) | UY28693A1 (es) |
WO (1) | WO2005063754A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109415347A (zh) * | 2016-05-03 | 2019-03-01 | 拜耳制药股份公司 | 酰胺取代的吡啶基三唑衍生物及其用途 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
TW200626154A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
US7923563B2 (en) | 2004-10-26 | 2011-04-12 | Eisai R&D Management Co., Ltd. | Amorphous object of cinnamide compound |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
EP1917255A2 (en) * | 2005-07-29 | 2008-05-07 | F. Hoffmann-Roche AG | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
AU2007329066B2 (en) * | 2006-12-07 | 2012-04-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
WO2008068185A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
US7501432B2 (en) * | 2006-12-22 | 2009-03-10 | Hoffman-La Roche Inc. | Spiro-piperidine derivatives |
ATE486877T1 (de) * | 2006-12-29 | 2010-11-15 | Hoffmann La Roche | Azaspiroderivate |
CL2008000582A1 (es) | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
TW200916469A (en) | 2007-08-31 | 2009-04-16 | Eisai R & Amp D Man Co Ltd | Multi-cyclic compounds |
EP2358202B1 (en) * | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
EP2623499B1 (en) | 2010-10-01 | 2015-04-22 | Taisho Pharmaceutical Co., Ltd | 1,2,4-triazolone derivative |
US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
CN105814013A (zh) | 2013-12-12 | 2016-07-27 | 卡利拉制药公司 | 双环烷基化合物及合成 |
JP6741343B2 (ja) | 2014-03-07 | 2020-08-19 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | プロペラン誘導体および合成 |
JP6833677B2 (ja) * | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 二環式化合物 |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
MA40893B1 (fr) * | 2014-11-03 | 2018-11-30 | Bayer Pharma AG | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
RU2637101C2 (ru) * | 2016-01-11 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) | Устройство для определения аспирированной дозы аэрозолей |
EP3419626A1 (en) * | 2016-02-23 | 2019-01-02 | Servicio Andaluz De Salud | Piperazine derivatives as antiviral agents with increased therapeutic activity |
AR108263A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
EP3452457B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US20190119251A1 (en) | 2016-05-03 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
JP6710273B2 (ja) * | 2016-05-09 | 2020-06-17 | 日本曹達株式会社 | 環状アミン化合物および有害生物防除剤 |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
CA3063729A1 (en) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081306A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CA3084308A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
AU2018356352A1 (en) | 2017-10-24 | 2020-04-16 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
CA3084411A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素V1a受體拮抗劑之三環化合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058880A1 (fr) * | 2000-02-08 | 2001-08-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481360A (en) * | 1983-08-26 | 1984-11-06 | The Upjohn Company | 4H-1,2,4-Triazol-3-yl compounds |
CA2409819C (en) * | 2000-05-19 | 2009-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Triazole derivatives |
-
2004
- 2004-12-09 EA EA200600925A patent/EA010132B1/ru not_active IP Right Cessation
- 2004-12-09 BR BRPI0417267-1A patent/BRPI0417267A/pt active Search and Examination
- 2004-12-09 JP JP2006546356A patent/JP4698604B2/ja not_active Expired - Fee Related
- 2004-12-09 GE GEAP20049469A patent/GEP20084571B/en unknown
- 2004-12-09 AP AP2006003631A patent/AP2331A/xx active
- 2004-12-09 OA OA1200600206A patent/OA13347A/en unknown
- 2004-12-09 KR KR1020067012328A patent/KR100854872B1/ko not_active IP Right Cessation
- 2004-12-09 AU AU2004309164A patent/AU2004309164B2/en not_active Ceased
- 2004-12-09 WO PCT/IB2004/004059 patent/WO2005063754A1/en active Application Filing
- 2004-12-09 CA CA2551038A patent/CA2551038C/en not_active Expired - Fee Related
- 2004-12-09 EP EP04801354A patent/EP1701959A1/en not_active Withdrawn
- 2004-12-17 TW TW093139507A patent/TWI287541B/zh active
- 2004-12-21 UY UY28693A patent/UY28693A1/es unknown
- 2004-12-21 NL NL1027833A patent/NL1027833C2/nl not_active IP Right Cessation
- 2004-12-21 AR ARP040104826A patent/AR047340A1/es not_active Application Discontinuation
- 2004-12-22 DO DO2004001062A patent/DOP2004001062A/es unknown
- 2004-12-22 PA PA20048620501A patent/PA8620501A1/es unknown
-
2005
- 2005-01-03 PE PE2005000032A patent/PE20051051A1/es not_active Application Discontinuation
-
2006
- 2006-05-18 IS IS8472A patent/IS8472A/is unknown
- 2006-06-15 IL IL176349A patent/IL176349A/en not_active IP Right Cessation
- 2006-06-15 EC EC2006006647A patent/ECSP066647A/es unknown
- 2006-06-22 CR CR8481A patent/CR8481A/es not_active Application Discontinuation
- 2006-06-22 MA MA29125A patent/MA28393B1/fr unknown
- 2006-07-21 NO NO20063380A patent/NO20063380L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07102965.0A patent/HK1095822A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058880A1 (fr) * | 2000-02-08 | 2001-08-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109415347A (zh) * | 2016-05-03 | 2019-03-01 | 拜耳制药股份公司 | 酰胺取代的吡啶基三唑衍生物及其用途 |
CN109415347B (zh) * | 2016-05-03 | 2021-05-07 | 拜耳制药股份公司 | 酰胺取代的吡啶基三唑衍生物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
HK1095822A1 (en) | 2007-07-06 |
BRPI0417267A (pt) | 2007-04-17 |
NL1027833A1 (nl) | 2005-06-23 |
JP4698604B2 (ja) | 2011-06-08 |
CR8481A (es) | 2007-12-04 |
NO20063380L (no) | 2006-09-22 |
PA8620501A1 (es) | 2005-08-04 |
DOP2004001062A (es) | 2005-06-30 |
KR20060101546A (ko) | 2006-09-25 |
IS8472A (is) | 2006-05-18 |
JP2007515468A (ja) | 2007-06-14 |
TW200528099A (en) | 2005-09-01 |
CA2551038A1 (en) | 2005-07-14 |
TWI287541B (en) | 2007-10-01 |
EA200600925A1 (ru) | 2006-12-29 |
AP2006003631A0 (en) | 2006-06-30 |
EP1701959A1 (en) | 2006-09-20 |
MA28393B1 (fr) | 2007-01-02 |
AU2004309164B2 (en) | 2007-11-15 |
ECSP066647A (es) | 2006-10-25 |
EA010132B1 (ru) | 2008-06-30 |
IL176349A (en) | 2011-11-30 |
GEP20084571B (en) | 2008-12-25 |
AU2004309164A1 (en) | 2005-07-14 |
CA2551038C (en) | 2010-04-27 |
WO2005063754A1 (en) | 2005-07-14 |
OA13347A (en) | 2007-04-13 |
AP2331A (en) | 2011-12-05 |
UY28693A1 (es) | 2005-07-29 |
PE20051051A1 (es) | 2005-12-17 |
NL1027833C2 (nl) | 2006-03-06 |
AR047340A1 (es) | 2006-01-18 |
IL176349A0 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100854872B1 (ko) | 바소프레신 길항제로서의 트리아졸 유도체 | |
US8093400B2 (en) | Compounds useful in therapy | |
US20080234252A1 (en) | Compounds Useful in Therapy | |
US20080188478A1 (en) | Compounds Useful In Therapy | |
US20070225333A1 (en) | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | |
US20070167430A1 (en) | Compounds useful in therapy | |
US7449462B2 (en) | Triazole derivatives which inhibit vasopressin antagonistic activity | |
ZA200604096B (en) | Triazole derivatives as vasopressin antagonists | |
MXPA06006155A (es) | Derivados de triazol como antagonistas de vasopresina | |
MXPA06008355A (es) | Derivados de triazol que inhiben actividad antagonista de vasopresina | |
CA2554090A1 (en) | Triazole derivatives which inhibit vasopressin antagonistic activity | |
MXPA06007563A (es) | Compuestos utiles en terapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110728 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20120727 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |